๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males

โœ Scribed by B. Ljungberg; I. Nilsson-Ehle

Publisher
Springer
Year
1988
Tongue
English
Weight
950 KB
Volume
34
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetics and bioavailability of
Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers
โœ Jamie J. Zhao; J. Douglas Rogers; Sherry D. Holland; Patrick Larson; Raju D. Ami ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 140 KB ๐Ÿ‘ 1 views

A study was conducted to (i) characterize the multiple-dose pharmacokinetics of oral montelukast sodium (MK-0476), 10 mg d 71 in healthy young subjects (N 12), (ii) evaluate the pharmacokinetics of montelukast in healthy elderly subjects (N 12), and (iii) compare the pharmacokinetics and oral bioava

THE EFFECT OF FOOD ON THE PHARMACOKINETI
THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF MULTIPLE-DOSE TERBINAFINE IN YOUNG AND ELDERLY HEALTHY SUBJECTS
โœ JERRY NEDELMAN; JEFFREY A. CRAMER; BRUCE ROBBINS; EKATERINA GIBIANSKY; CHENG-TAO ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 669 KB

Pharmacokinetic (PK) parameters for terbinaยฎne were assessed in 15 elderly and 15 young healthy subjects randomized to receive 250 mg Lamisil 1 once daily for 15 d in a two-period, two-treatment, two-sequence, crossover (fed versus fasted) design within age groups. On each treatment day except days

Single-dose pharmacokinetics of nefazodo
Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment
โœ R. H. Barbhaiya; D. S. Greene; U. A. Shukla ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› Springer ๐ŸŒ English โš– 658 KB

The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < 55 years of age (YNG), 12 elderly subjects > 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis